TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient older than 18 years~* Inoperable (advanced or metastatic) HCC histologically proven, or diagnosed according to the Barcelona criteria, determined to be candidate for Sorafenib therapy~* Lesion(s) able to be selected as targeted lesion(s) for modified RECIST criteria~* patient ineligible for curative treatment~* Child-Pugh liver function (platelet count superior or equal to 60X1 000 000 000per liter; haemoglobin superior or equal to 8,5g/dl~* Performance status more or equal to 2~* Able to lie still for 45min for PET/CT scanning~* Able to understand and willing to signa written informed consent document~* Affiliated to the French social security social or beneficiary to such a regimen~Exclusion Criteria:~* Uncontrolled intercurrent illness with short-term life-threatening~* Pregnant or nursing woman~* Patient candidate to local/curative therapy of HCC (surgery, radiofrequency, transarterial chemoembolization, other local therapy).~* History of myocardial infarction less than 6 months before inclusion, uncontrolled hypertension, symptomatic congestive heart failure, anti-arrhythmic therapy (other than beta-blockers or digoxine)~* History of digestive bleeding less than 30 days before inclusion~* history of liver transplantation~* Previous treatment including Sorafenib Uncontrolled diabetes History of allergic reactions attributed to compounds of similar chemical or biologic composition to Fluorocholine, 18F-Fluorodeoxyglucose or Sorafenib~* Psychiatric illness/social situations that would limit compliance with the study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- FDG and FCH PET (Type: EXPERIMENTAL): Patients will performed a TEP with 2 different radiotracer before treatment is started and 1 month after treatment has been started.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Aspirin and Plavix Following Coronary Artery Bypass Grafting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing coronary artery bypass grafting, with or without cardiopulmonary bypass~* Age ≥ 18~Exclusion Criteria:~* Left ventricle ejection fraction \<30%~* Emergency surgery~* Valve surgery~* Redo CABG~* Postoperative cardiogenic shock for more than 48 hours~* Postoperative bleeding or cardiac tamponade~* More than 24 hours postoperative intubation course~* Requirement of postoperative anticoagulation~* Serum creatinine \>1.4~* Contraindication to use of postoperative coronary CT scan~* Allergy or contraindication to aspirin or clopidogrel~* Inability to provide informed consent~* Pregnant or breast feeding females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- clopidogrel (Type: ACTIVE_COMPARATOR): aspirin and clopidogrel
- sugar pill (Type: PLACEBO_COMPARATOR): aspirin and placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pre-meal Protein Drink Improve Glycemic Regulation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed type 2 diabetes mellitus according to WHO criteria (1999)~* age between 30-80 years~* non well controlled diabetes with HbA1c-levels above 62 mmol/mol~Exclusion Criteria:~* pregnant or risk of becoming pregnant~* severe disease~* psychological disease, dementia or mental disability that makes it impossible to retrieve informed consent of participation~* liver disease~* kidney malfunction (GFR \<60 or aspartate transaminase (ASAT)/alanine transaminase (ALT) two times higher than the normal interval

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Pre-meal protein drink (Type: EXPERIMENTAL): A dose of 100 ml is taken just before breakfast, lunch and dinner.
- Water drink (Type: PLACEBO_COMPARATOR): A dose of 100 ml is taken just before breakfast, lunch and dinner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety Study of PRALUENT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~Participants randomized into the neurocognitive function study (R727-CL-1532) who completed treatment and the end of study (EOS) visit with no premature or permanent discontinuation of study drug.~Key Exclusion Criteria:~1. Significant protocol deviation in the parent study (neurocognitive function study R727-CL-1532: NCT02957682) based on the investigator's or sponsor's judgment, such as noncompliance~2. Any participant who experienced an AE leading to permanent discontinuation from the neurocognitive function study R727-CL-1532 (NCT02957682).~3. Any new condition or worsening of an existing condition which, in the opinion of the investigator or per the PRALUENT local label, would make the participant unsuitable for enrollment or could interfere with the participant participating in or completing the open-label extension (OLE) study~4. Known hypersensitivity to monoclonal antibody or any component of the drug product~5. Pregnant or breastfeeding women~Note: Other inclusion/ exclusion criteria apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Open label (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Molecular Imaging of Breast Cancer With Breast PET/CT

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~- Normal Adult Volunteers~* Female, at least 18 years of age~* Ability to lie motionless for up to 20 minutes~Patient Volunteers~* Female, at least 18 years of age~* Diagnostic findings from prior mammography highly suggestive of invasive breast carcinoma (BI-RADS category 5)~* Not pregnant or breast-feeding~* Ability to lie motionless for up to 20 minutes~Exclusion Criteria:~* Normal Adult Volunteers~  * Inability to understand the risks and benefits of the study~Patient Volunteers~* Recent breast biopsy~* Diagnostic findings from prior mammography highly suggestive of noninvasive ductal or lobular carcinoma~* Uncontrolled diabetes~* Diabetic and blood sugar level \> 200 mg/dL~* Positive urine pregnancy test or currently breast-feeding~* Inability to understand the risks and benefits of the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: OTHER): Normal volunteers
- 2 (Type: ACTIVE_COMPARATOR): Breast PET/CT scan
- 3 (Type: ACTIVE_COMPARATOR): Whole body and breast PET/CT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Palliative Care for Non-Malignant Diseases (COMPASS Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inpatient at Vanderbilt University Medical Center with advanced cirrhotic liver disease, whose treating hepatologist indicates a 'No' response to the question, Would you be surprised if this patient died within 1 year?~Exclusion Criteria:~* Age \< 18 years~* Receipt of liver transplant at the time of potential enrollment~* Inability to give written informed consent (patient or surrogate decision-maker)~* Inability to respond to questions in English~* Treating hepatologist denies permission to enroll~* Receiving hepatology care at non-Vanderbilt sites (to ensure appropriate follow-up)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Comprehensive Palliative Care services (Type: OTHER): Comprehensive Palliative Care services in addition to usual hepatic care
- Usual hepatic care (Type: OTHER): Usual hepatic care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multimodal Treatment Strategy for Cancer Cachexia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Are referred to the Cachexia Clinic with involuntary weight loss of \>5% of their premorbid weight within the previous 6 months.~2. Are 18 years of age or older~3. Have a Karnofsky performance score of 60 or higher.~4. Can maintain oral food intake during the study~5. Can understand the study procedures and can sign an informed consent form.~6. Are not currently taking melatonin.~7. Are taking megestrol acetate and continue to lose weight despite at least 2 weeks of therapy.~8. Have a calculated creatinine clearance of \>/= 60 cc/min.~Exclusion Criteria:~1. Have dementia or delirium (as determined by the palliative care specialist) at study entry.~2. Are pregnant~3. Have been taking corticosteroids for longer than 48 hours.~4. Have pulmonary edema, ascites or pitting edema on clinical examination.~5. Are unable to walk.~6. Have a history of serious adverse gastrointestinal events (i.e., bleeding or perforation),history of a coagulopathy or current anti-coagulant use.~7. Have an ALT/AST\>3x upper limit of normal.~8. Patients on methotrexate.~9. Patients taking melatonin receptor agonists (such as Rozerem® \[ramelteon\]).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Multimodal Treatment Strategy (Type: EXPERIMENTAL): Exercise Program + Pharmacologic Intervention (Melatonin + Atenolol + Ibuprofen) + Nutritional Supplementation (Juven) - Resistance training sessions twice weekly using Thera-bands. Walking or running for 3-4 minutes at 70-80% of maximum predicted heart rate. Melatonin 20 mg by mouth (PO) Daily. 90 calories of Juven, twice a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Females elder than 18~2. Histological proven unresectable or metastatic breast cancer patients who underwent at least one chemotherapy regimen for metastatic disease~3. Patients with androgen Receptor (AR) positive (IHC \>10% nuclear staining) either for primary tumor or metastatic lesion~4. Triple-negative for estrogen receptor (ER), progestogen receptor (PR), and human epithelial receptor-2 (HER2) by IHC (ER \<1%, PR \<1% and Her2 negative). A negative Her2 gene amplification should be verified by FISH test for those patients with Her2 (2+). For those with Her2 (1+), FISH test might be considered by the investigator.~5. At least one measurable disease according to the response evaluation criteria in solid tumor (RECIST 1.1)~6. Performance status no more than 2~7. All patients enrolled are required to have adequate hematologic, hepatic, and renal function~8. Life expectancy longer than 12 weeks~9. No serious medical history of heart, lung, liver and kidney~10. Be able to understand the study procedures and sign informed consent.~11. Patients with good compliance~Exclusion Criteria:~1. Pregnant or lactating women~2. Women of child-bearing potential, unwilling to use adequate contraceptive protection during the process of the study~3. Patients treated with an investigational product within 4 weeks before the enrollment~4. Patients who received chemotherapy within 4 weeks before the enrollment~5. Patients with symptomatic central nervous system metastases are not permitted, except for those with stable and asymptomatic brain metastases who have completed cranial irradiation, and have at least one measurable lesion outside the brain. Radiotherapy should be completed within 4 weeks prior to the registration~6. Other active malignancies (including other hematologic malignancies) or other malignancies within the last 5 years, except for cured nonmelanoma skin cancer or cervical intraepithelial neoplasia.~7. Patients having a history of clinically significant cardiovascular, hepatic, respiratory or renal diseases, clinically significant hematological and endocrinal abnormalities, clinically significant neurological or psychiatric conditions~8. Uncontrolled serious infection

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- bicalutamide (Type: EXPERIMENTAL): 150mg, po, qd, d1-28

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of breast cancer~* Metastatic or incurable~* Prior treatment with an anastrozole or letrozole and a CDK4/6 inhibitor~* Progression while on or within 6 months of stopping the CDK4/6 inhibitor~* At least one lesion amenable to percutaneous biopsy that is not a purely sclerotic bone lesion~* ECOG 0-2~* Age 18 or greater~* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.~Exclusion Criteria:~* Prior treatment within 2 years with fulvestrant, alpelisib, everolimus, or capecitabine~* Comorbid disease other than breast cancer with a life expectancy of less than 2 years~* Cancer other than breast cancer that is expected to need treatment within 2 years~* Platelets \< 100,000/microliter~* INR \> 1.5

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Microwave Ablation in Mild Axillary Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (≥ 18 years of age) male or female patients with mild HS and able to participate, willing to give written informed consent and to comply with the study restrictions;~* Minimum of 3 AN-count located in each axilla;~* Maximum of 5 AN-count located in each axilla.~Exclusion Criteria:~* Patients with \>1 abscesses or draining fistulas per axillary region;~* AN-count ≥ 5 in other regions than the axillary area;~* Any current and / or recurrent clinically significant skin condition in the treatment area other than HS;~* Surgical scars covering more than 25% of each individual axillary area;~* Open surgical wound(s) in the axillary areas prior to randomization;~* Use of anti-inflammatory or immunomodulatory medication (intralesional corticosteroids, oral antibiotics, biologics, prednisone) within 2 weeks prior to randomization;~* Contraindication for miraDry therapy;~* Heart pacemakers and other electronic device implants;~* Supplemental oxygen;~* Resistance to or history of intolerance of local anesthesia including lidocaine and epinephrine;~* Previous use of miraDry therapy or MWA in the axillary area;~* Previous use of successful laser or light therapy for hair removal in the axillary area;~* Use of botulinum toxin injections 6 months prior to randomization;~* Use of aluminiumhydroxychloride 1 month prior to randomization;~* Pregnant or lactating women at randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Microwave ablation (Type: EXPERIMENTAL): One-sided single microwave ablation (MWA) treatment in one axillary region with a miraDry device.
- No microwave ablation (Type: NO_INTERVENTION): Lesion intervention in the non-MWA treated contralateral axilla consists of once daily topical clindamycin 1% lotion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Young Adult Naturalistic Alcohol Study (YANAS) Using Smartphone Technology in a Simulated Laboratory Environment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Be able to read English and complete assessments~* Drink alcohol regularly~Exclusion Criteria:~* Test positive on a urine test for use of certain illegal drugs~* Undergraduate student enrolled in the University of Florida~* Graduate students from the College of Health and Human Performance at the University of Florida~* Pregnant, or breast feeding

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Smartphone breathalyzer device & app (Type: None): This is a small device that attaches to a smartphone with an accompanying app that produces accurate breath alcohol readings when a user blows into a small tube attached to the device. Participants randomized to this study condition will have the opportunity to use this device and app during an alcohol drinking session in a simulated laboratory.
- BAC estimator app (Type: None): This is an app that produces estimated blood alcohol content (eBAC) readings based on sex, weight, number of drinks and time taken to consume drinks. Participants randomized to this study condition will have the opportunity to use this app during an alcohol drinking session in a simulated laboratory.
- Text Messaging (Type: None): A procedure whereby one sends a text message to the phone one is using after each alcoholic drink. Participants randomized to this study condition will have the opportunity to the text messaging procedure during an alcohol drinking session in a simulated laboratory.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Low Energy Surface Waves for Neurogenic Bladder Patients With Indwelling Catheters

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. \>18 years of age~2. Spinal cord injury (\>1 year), multiple sclerosis (\>1 year), spina bifida, parkinsons (\>1 year)~3. Indwelling catheter (urethral or suprapubic) for \>3 months, and used as primary bladder management mechanism~4. \>1 urinary tract infection in the last 12 months~Exclusion Criteria:~1. Intravesical botox in the last 6 months~2. Chronic antibiotic suppressive therapy~3. Active symptomatic UTI on day of randomization~4. Unable to understand written and spoken English~5. Prior/current utilization of the Uroshield device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sham (Type: SHAM_COMPARATOR): Inactive uroshield device
- Active Uroshield (Type: EXPERIMENTAL): Active uroshield device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of endogenous Cushing's syndrome~* Baseline UFC 1.3 to 10 × upper limit of normal (ULN)~* If previous pituitary surgery, participants must be at least 3 months since surgery at the time of screening~* BMI between 18 and 60 kg/m2, inclusive~Exclusion Criteria:~* Pseudo-Cushing's syndrome, cyclic Cushing's syndrome or current iatrogenic Cushing's syndrome~* Candidates for surgical treatment of Cushing's syndrome, unless surgery is not anticipated to occur during the study~* Normal late night salivary cortisol or 24-hr urine free cortisol~* Radiotherapy of the pituitary within 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ATR-101 (Type: EXPERIMENTAL): During the 4-week randomized withdrawal period, eligible subjects will receive ATR-101 at the same dose level being used at the completion of the open-label dose-escalation period.
- Placebo (Type: PLACEBO_COMPARATOR): During the 4-week randomized withdrawal period, eligible subjects will receive a placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues